VistaGen Therapeutics (VTGN) Q1 2025 earnings summary

Executive summary

• Developing non-systemic, neurocircuitry-focused nasal spray treatments for social anxiety disorder (SAD), major depressive disorder (MDD), and menopausal hot flashes, targeting large markets with unmet needs.

• Lead program is the PALISADE phase III program for fasedienol in SAD, with PALISADE-3 underway and PALISADE-4 planned for H2 2024; top-line results expected in 2025.

• Itruvone for MDD and PH80 for menopausal hot flashes are advancing, with IND-enabling and Phase II/IIb planning ongoing.

• Positive phase III results for fasedienol in PALISADE-2; Fast Track designation granted for fasedienol in SAD and itruvone in MDD.

• Net loss attributable to common shareholders was $10.7 million for the quarter ended June 30, 2024, with continued losses expected as R&D activities expand.

Financial highlights

• Research and development expenses were $7.6 million for Q1 FY2025, up from $4.2 million year-over-year, mainly due to increased clinical activity and headcount.

• General and administrative expenses rose to $4.6 million from $3.0 million year-over-year, reflecting higher headcount and professional service costs.

• Net loss for the quarter was $10.7 million, compared to $6.9 million in the prior year.

• Cash, cash equivalents, and marketable securities totaled $108.4 million as of June 30, 2024.

• Revenue for the quarter was $0.1 million, down from $0.2 million year-over-year, primarily from sublicense and collaboration agreements.

Outlook and guidance

• Enrollment for PALISADE-3 is on track; PALISADE-4 is set to initiate in H2 2024, with both studies expected to read out in 2025.

• Phase IIb trial for itruvone in MDD is being finalized, with protocol submission to the FDA planned before year-end; trial start not expected before year-end.

• Ongoing non-clinical work for PH80 aims to enable U.S. phase II development for menopausal hot flashes.

• Management expects R&D and G&A expenses to increase substantially as the pipeline advances; current cash resources expected to fund operations for more than 12 months.

• The company anticipates continued net losses and negative cash flows as it progresses clinical and preclinical programs.